Posts Tagged ‘anti-obesity medicines’

OMG. How can we possibly cope with the costs of treating obesity with these expensive new obesity meds? This question seems to be on the lips of many who pay for health plans. But a new study in Nature Communications turns that question on its head. How can we afford to continue withholding effective treatment for […]

At IFSO 2023 in Naples, it was clear the people are keenly aware. Change is afoot in obesity care. New obesity medicines are starting to produce clinical outcomes that approach the outcomes people see with surgery So the recurrent question at the meeting was all about what might be on the horizon for metabolic surgery. […]

This comes as an early morning post of anticipation. Right now we are in a dark plane over the North Atlantic, anticipating two things. First we anticipate two intense days that will begin with a jolt as we land in a bright (and possibly wet) morning in Naples, Italy, for the IFSO meeting that started […]

Writing for the New York Times, Joseph Goldstein tells us that prescriptions for GLP-1 agonists are going to the wealthiest, whitest, and healthiest neighborhoods in New York City. Neighborhoods where the medical need is greatest? Not so much. Though we might hope that advanced medicines for obesity and diabetes would go to places with the […]

Scientists who study semaglutide in obesity are producing a steady stream of impressive results. Yesterday in the New England Journal of Medicine, a randomized controlled trial in persons with obesity and heart failure with preserved ejection fraction demonstrated superior weight reduction, improvement in heart failure, better physical functioning, and a halving of serious adverse events. […]

A new study of real world primary non-adherence (PNA, not filling an Rx) for obesity medicines provides documentation for something that should surprise no one. More than 90% prescriptions for obesity meds are never filled. Writing in the Journal of Managed Care + Specialty Pharmacy, Hong Kan and colleagues say this is unusual, especially for […]

We are clearly on a path toward better obesity medicines, but reflecting on decades of work on this, clearly, the path is twisted. Describing this path, Gina Kolata writes: “Every so often a drug comes along that has the potential to change the world. Medical specialists say the latest to offer that possibility are the […]

“If you thought that GLP-1 agonists would replace bariatric surgery you are wrong.” Neil Floch is not alone in saying this and new research adds to the reasons we suspect that he is right. In JAMA Surgery, Jessica Mok and colleagues tell us that one plus one equals three with the combination of bariatric surgery […]

Headline writers are fond these days of depicting a “craze” among prescription writers for new obesity medicines. But in fact, it seems that long-standing prescribing patterns may promote more weight gain than weight loss. A new paper by Erik Almazan, Jessica Schwartz, and Kimberly Gudzune documents prescribing for medicines that promote weight gain in 36 percent […]

Calm in the midst of a storm is always odd. Has it passed? Or is there more to come? Bedlam pretty much defines the market for obesity care right now. Both Novo Nordisk and Lilly announced robust business results on the strength of impressive new options for treating obesity. Novo released stunning topline results for […]